DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):

Phase 1

Not yet recruiting

Conditions: Gastroesophageal Adenocarcinoma

Interventions: Drug: toripalimab FOLFOX

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-14

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 126

Registration Number: NCT05986227

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer
Neoadjuvant Therapy

Interventions: Drug: Utidelone
Drug: Carboplatin
Drug: Epirubicin
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2023-08-09

Last Posted Date: 2023-08-09

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 181

Registration Number: NCT05983094

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Phase 2

Recruiting

Conditions: HR+/HER2- Advanced Breast Cancer
Targeted Therapy

Interventions: Drug: Everolimus
Drug: Chidamide
Drug: Endocrine therapy
Drug: Ovarian function suppression(OFS)

First Posted Date: 2023-08-09

Last Posted Date: 2023-08-09

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 102

Registration Number: NCT05983107

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Neoadjuvant immunochemotherapy
Drug: Neoadjuvant chemotherapy

First Posted Date: 2023-08-03

Last Posted Date: 2023-08-03

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 1500

Registration Number: NCT05974007

Locations: 🇨🇳
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Phase 2

Recruiting

Conditions: Tislelizumab
MSS/pMMR
RAS-mutated
Oxaliplatin
First-Line
Bevacizumab
Capecitabine
Metastatic Colorectal Cancer (mCRC)

Interventions: Drug: Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine

First Posted Date: 2023-08-01

Last Posted Date: 2023-08-01

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 52

Registration Number: NCT05970302

Locations: 🇨🇳
Lin Yang, Beijing, China

Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC

Not Applicable

Active, not recruiting

Conditions: Esophageal Squamous Cell Carcinoma
Oligometastatic Disease

Interventions: Procedure: Esophagectomy

First Posted Date: 2023-07-18

Last Posted Date: 2023-07-18

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 141

Registration Number: NCT05951127

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma

Phase 2

Recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Fluzoparib
Radiation: Preoperative moderately fractionated radiotherapay

First Posted Date: 2023-07-10

Last Posted Date: 2023-07-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT05938374

Locations: 🇨🇳
Cancer Hospital and Institute, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical Center, Beijing, Beijing, China
🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China

Safety and Feasibility of Laparoscopic Intracorporeal Anastomosis for Colorectal Surgery- A Multiple Center Real World Study

Recruiting

Conditions: Colorectal Cancer

Interventions: Procedure: Intracorporeal anastomosis

First Posted Date: 2023-06-20

Last Posted Date: 2023-06-27

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 2000

Registration Number: NCT05911152

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC

Phase 2

Not yet recruiting

Conditions: Lung Neoplasms

Interventions: Drug: Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)
Drug: Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)

First Posted Date: 2023-06-15

Last Posted Date: 2023-06-15

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 80

Registration Number: NCT05904015

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC

Phase 2

Recruiting

Conditions: Local Advanced Non-small Cell Lung Cancer

Interventions: Radiation: Concurrent chemoradiation therapy and consolidation immunotherapy
Drug: Toripalimab

First Posted Date: 2023-06-05

Last Posted Date: 2023-08-29

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 50

Registration Number: NCT05888402

Locations: 🇨🇳
Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy